Key statistics
As of last trade AGC Inc (5201:TYO) traded at 6,353.00, -0.90% below its 52-week high of 6,411.00, set on Feb 17, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 6,405.00 |
|---|---|
| High | 6,411.00 |
| Low | 6,330.00 |
| Bid | 6,353.00 |
| Offer | 6,357.00 |
| Previous close | 6,360.00 |
| Average volume | 1.63m |
|---|---|
| Shares outstanding | 217.43m |
| Free float | 197.71m |
| P/E (TTM) | 19.34 |
| Market cap | 1.37tn JPY |
| EPS (TTM) | 326.18 JPY |
| Annual div (ADY) | 210.00 JPY |
|---|---|
| Annual div yield (ADY) | 3.30% |
| Div ex-date | Dec 29 2025 |
| Div pay-date | Mar 30 2026 |
| Next div ex-date | Jun 29 2026 |
| Next div pay-date | Sep 01 2026 |
Data delayed at least 15 minutes, as of Feb 17 2026 00:11 GMT.
More ▼
Press releases
- AGC Biologics Seattle Site Now Certified to Manufacture Biologics for Largest Pharmaceutical Market in South America
- AGC Biologics Celebrates U.S. and EU Approval of Fondazione Telethon’s Waskyra™ Treatment for Wiskott-Aldrich Syndrome
- Asimov and AGC Biologics Team Up to Provide a Cost-Effective, Simplified, and Secure Manufacturing Approach for Viral Vector Production
- AGC Biologics Partners with ATUM to Accelerate Timelines for Cell Line Development
- AGC Biologics to Manufacture AAVantgarde’s Dual-Vector Gene Therapies for Inherited Retinal Disorders
- AGC Biologics and Repair Biotechnologies Partner on Novel mRNA Therapeutic to Combat the Leading Cause of Human Mortality
More ▼
